MYGN
Myriad Genetics Inc
4.20$
+0.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 23.1% | 27.4% | 26.1% | 26.9% | 27.1% | 29.0% | 28.5% | 42.0% | 47.4% | 47.1% | 46.4% | 45.2% | |
| 6.6% | 11.5% | 8.7% | 8.5% | 9.2% | 10.0% | 9.1% | 11.0% | 20.0% | 21.2% | 18.5% | 18.0% | |
| 7.5% | 12.3% | 9.4% | 9.0% | 9.2% | 10.0% | 9.1% | 11.0% | 20.0% | 21.2% | 18.5% | 18.0% | |
| 10.0% | 10.0% | 10.6% | 10.9% | 11.6% | 11.8% | 12.0% | 20.2% | 16.2% | 16.3% | 18.4% | 17.1% | |
| 2.2% | 1.9% | 2.2% | 2.4% | 2.4% | 2.7% | 2.8% | 4.2% | 4.3% | 4.3% | 4.1% | 4.8% | |
| 24.9% | 25.1% | 25.8% | 26.4% | 26.5% | 27.9% | 28.5% | 7.6% | 7.1% | 7.3% | 7.0% | 7.4% | |
| 31.0% | 30.5% | 30.7% | 29.4% | 28.9% | 25.5% | 25.6% | 25.0% | 22.4% | 21.7% | 21.6% | 21.8% | |
| 40.5% | 31.7% | 31.6% | 31.8% | 32.3% | 31.8% | 29.9% | 42.7% | 48.8% | 47.9% | 49.9% | 52.4% | |
| 18.2% | 13.6% | 13.2% | 13.7% | 14.3% | 16.0% | 15.0% | 29.5% | 20.3% | 18.9% | 19.3% | 20.5% | |
| 1.5% | 1.4% | 1.2% | 1.2% | 1.2% | 1.2% | 1.1% | 10.1% | 1.1% | 1.0% | 1.1% | 1.1% | |
| 3.0% | 2.3% | 3.0% | 3.1% | 2.7% | 3.1% | 2.8% | 4.6% | 4.4% | 4.2% | 4.8% | 4.8% | |
| 3.4% | 3.4% | 3.5% | 3.6% | 3.6% | 3.9% | 5.9% | – | 16.4% | 17.0% | 17.9% | 18.9% | |
| 59.5% | 68.3% | 68.4% | 68.2% | 67.7% | 68.2% | 70.1% | 57.3% | 51.2% | 52.1% | 50.1% | 47.6% | |
| -52.1% | -54.9% | -59.0% | -63.8% | -66.1% | -73.6% | -75.2% | -160.5% | -153.1% | -158.9% | -171.7% | -187.8% | |
| 7.1% | 7.5% | 8.1% | 8.3% | 8.4% | 8.9% | 9.1% | 13.7% | 12.8% | 13.2% | 13.9% | 14.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.